Trial Profile
Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic Focal Segmental Glomerulosclerosis: A Prospective Study of Acthar (PODOCYTE)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Aug 2021
Price :
$35
*
At a glance
- Drugs Corticotropin (Primary)
- Indications Proteinuria
- Focus Adverse reactions
- Acronyms PODOCYTE
- Sponsors Mallinckrodt plc
- 23 Nov 2020 Trial focus changed from TU to AR. Study design changed to open, prospective, multicenter instead of parallel, double blind, and randomized. Treatment arms reduced from 4 to 1.
- 27 Aug 2020 Status changed from active, no longer recruiting to completed.
- 15 May 2020 Planned End Date changed from 1 Apr 2020 to 28 Aug 2020.